Stem Cells Inducing Remission for Multiple Sclerosis

HDIT/HCT is a new medical approach that is going to benefit the patients and make the work of the neurologist like Dr Shiva Vasishta easier. The treatment will induce remission of the Multiple Sclerosis.

Multiple Sclerosis is an autoimmune disease where your immune system attacks the Central Nervous System. If this happens, you will experience chronic pain, weakness and speech difficult. The condition will worsen as the years go by and can lead to disability.

With the new medical condition, neurologists will be in a position to reduce the long-term remission. The patients will get a high dose of immunosuppressive therapy, and this will be followed by a stem transplant using the patient’s blood-forming cells.

There was a five-year trial on the treatment done on different patients. 69% of the patients in the trial period reported a decrease in MS. They also said they did not experience a progression of disability or a relapse

The study was done by the National Institute of Allergy and Infectious Disease, and it indicated that this treatment could produce better results than the long term conditions. Even though the current research that was done indicate that the treatment is safe, more research is still needed to check on the associated benefits and risks if any.

About Dr Shiva Vasishta

Dr Shiva Vasishta is a neurologist, and his patients are set to benefit from this treatment. He has over 30 years of experience in the field, and that is what makes him an expert on the subject.

Dr Shiva Vasishta graduated from the Government Medical College with a Medical Degree. He is one of the doctors who practice neurology at the Kennedy University Hospital. He practices at the Eastern Neurodiagnostic Associates.

Dr Shiva Vasishta also specialises in psychiatry.

New Drug Shows Promise in Stabilizing Multiple Sclerosis

Clinical trials have shown that scientists may have finally found a breakthrough in combatting relapsing-remitting multiple sclerosis (MS). The treatments consist of a high dose immunosuppressive therapy coupled up with an implant of the patient’s blood-forming stem cells. This therapy has proven that it can lessen the effects of MS, a condition which causes the immune system to attack the nervous system.

69% of patients who tried the new drug have lived on without experiencing new MS symptoms, brain complications or advancement of neurological disability. The drug, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT), has recorded a higher success rate than all of its competitors in the market.

The research was conducted by the National Institute of Allergy and Infectious Diseases (NIAID). Volunteers were MS patients between the age 26 and 52, who were taking other medications available which had adverse side effects to them. However, the use of HDIT/HCT proved to be safe and efficient.

The drug subdues the disease by removing the infected cell from the immune system. Doctors extract stem cells while administering the high dose therapy to suppress the immune system. The stem cells are then implanted back into the patient to reconstruct the immune system.

Realists showed massive improvements five years after taking the medication. Researchers aim to re-conduct the trial using a larger sample to increase the medication’s credibility. Although the therapy is still in its early stages, it has shown promise in the fight against MS.

Dr. Shiva’s Background

Dr. Shiva Gopal Vasishta is a neurologist based in Voorhees, New Jersey. He has practiced medicine for almost four decades. He graduated from Government Medical College in 1979.

Shiva Gopal Vasishta is a member of Medicare program hence he does not charge more than the approved amount if you are a Medicare member.

Additionally, Dr. Shiva Gopal Vasishta is an active member of the American board of psychiatry and neurology.